Eviangenics, a Paris, France-based biotech company generating new products and manufacturing processes for the chemical and pharmaceutical industry by applying an in vivo recombination technology, completed its €1.3m first round of funding.
Investors include CEA Investissement, EMERTEC, and CapDecisif Management.
The company intends to use the funds to commercialize its technology platform, in partnership with manufacturers, and develop new products addressing the needs of the chemical and pharmaceutical markets.
Led by Rudy Pandjaitan, Eviagenics has developed an in vivo recombination technology that is designed to insert and improve complete metabolic pathways in cells directly.
These reprogrammed cells will then be able to transform sugars from cheap renewable sources like feedstock into numerous new high value compounds.
The company’s resulting products will be designed to reduce costs for energy as well as toxic emissions and waste (less CO2, organic solvents or toxic side products) and help to efficiently use limited resources (sugar, feedstock petrol). It will also address the growing demand of feed and pharmaceutical companies for sustainable products and manufacturing processes.